For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- M&A Inevitable for Japanese Drug Companies: Nikko Solomon's Analyst
September 24, 2001
- FY2001 Korosho White Paper Stresses Importance of Social Security as Safety Net
September 24, 2001
- 9 Active Ingredients to Be Approved in September
September 24, 2001
- PMSB to Take Measures to Ensure Quality of Imported Medical Devices
September 24, 2001
- REGULATORY NEWS IN BRIEF
September 24, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 24, 2001
- Taisho, Tanabe Agree to Integrate Their Business
September 24, 2001
- GEYMS Launches New Multislice CT "LightSpeed Ultra" in Japan First
September 24, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 24, 2001
- Terumo Takes Over Home Oxygen Business from Sumitomo Bakelite
September 24, 2001
- Sankyo to Give Greater Importance to Clinic Market for Life-style Diseases
September 24, 2001
- Takara Launches Nexell's Magnetic Cell Separation System from Nexell
September 24, 2001
- 51% of JPMA Member Firms Have Documented Compliance Programs
September 24, 2001
- Makers Outsource More OTC Drug Marketing Activities
September 24, 2001
- FJPWA Decides to Cooperate in Market Price Survey
September 24, 2001
- OTC NEWS IN BRIEF
September 24, 2001
- Wholesalers' Bargaining Ability to Be Tested in 2002
September 24, 2001
- WORLD NEWS IN BRIEF
September 24, 2001
- BUSINESS NEWS IN BRIEF -1-
September 24, 2001
- P450 DB Provides Valuable Information on Drug Interactions: FQS, Shionogi
September 24, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…